Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus anuncia una colocación privada sobresuscrita de hasta USD 340 millones para impulsar el ensayo registracional ROBBIN de BOT+BAL como tratamiento neoadyuvante del cáncer de colon MSS

Wednesday, July 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced a successful oversubscribed private placement, raising approximately USD 85 million initially, with the potential for an additional USD 255 million through warrants. This funding will support the pivotal ROBBIN trial for BOT+BAL as a neoadjuvant treatment for MSS colon cancer. The financing was led by Commodore Capital.
Price reaction · baseline $4.895 (2026-07-15T17:53:00.000Z) · hit during market hours · 2 other AGEN headline(s) in the window, move may be shared
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus secures significant funding to advance clinical trials.
  • The private placement is oversubscribed, indicating strong investor interest.
  • The funds will support the pivotal ROBBIN trial for a promising cancer treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Early Rectal Cancer

Full Press Release Details

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), empresa líder en innovación en inmunooncología, anunció hoy la firma de un acuerdo de compra de valores para una colocación privada que contempla ingresos brutos iniciales de aproximadamente USD 85 millones, antes de deducir los gastos de la operación, además de hasta USD 255 millones adicionales en caso de ejercerse la totalidad de los warrants de compra. La financiación fue liderada por Commodore Capital, con la participac

Frequently Asked Questions

What is the purpose of Agenus's private placement?

The private placement aims to raise funds to support the ROBBIN trial for BOT+BAL in treating MSS colon cancer.

How much funding did Agenus secure initially?

Agenus secured approximately USD 85 million initially from the private placement.

What is the total potential funding amount for Agenus?

The total potential funding could reach up to USD 340 million if all warrants are exercised.

Who led the financing for Agenus's funding?

The financing was led by Commodore Capital.

ShareAdd on Google
Tags: AGEN Agenus ROBBIN trial cancer treatment MSS colon cancer private placement
Last updated: Jul 15, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Early Rectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →